Chapter 13: Antiparkinsonian Drugs in Mental Health Care

Antiparkinsonian Drugs in Mental Health Care establishes the critical biochemical distinction between idiopathic Parkinson's disease (PD), which involves neurodegeneration of the substantia nigra and a loss of dopamine production, and drug-induced parkinsonism, which is caused by the blockade of dopamine receptors in the basal ganglia by psychotropic agents. A core concept explored is the delicate neurotransmitter balance between dopamine and acetylcholine (ACh); the text explains that while PD is treated with dopaminergics, EPSEs in patients with schizophrenia must be managed with anticholinergics to restore balance without exacerbating psychosis. The summary details the clinical presentation of various EPSEs, including akathisia (subjective restlessness), akinesia and bradykinesia (slowed movement), and acute dystonias (severe muscle spasms such as torticollis and oculogyric crisis). It also covers serious complications like Tardive Dyskinesia (TD), characterized by late-appearing, often irreversible oral-facial movements, and Neuroleptic Malignant Syndrome (NMS), a potentially fatal reaction marked by hyperthermia and rigidity. Pharmacological interventions are thoroughly analyzed, highlighting the use of anticholinergic agents like benztropine, trihexyphenidyl, and the antihistamine diphenhydramine to mitigate motor symptoms. Furthermore, the chapter delineates the side effect profile of these anticholinergic treatments, categorized into central nervous system effects such as confusion and cognitive decline, and peripheral nervous system effects including xerostomia (dry mouth), blurred vision (mydriasis), urinary retention, constipation, and tachycardia. The content concludes by emphasizing nursing implications, such as the increased vulnerability of older adults to toxicity, the importance of prevention through careful drug selection, and the necessity of patient education regarding safety and symptom management.